Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
نویسندگان
چکیده
β-Secretase is an attractive target of amyloid-reduction therapy for Alzheimer's disease. Currently, no efficacy data is available from clinical trials of β-secretase inhibitors. Treating young transgenic Tg2576 mice with a brain-penetrating β-secretase inhibitor reduced brain amyloid-β by about 50% and rescued the age-related cognitive decline. Implications from these model studies on the design of clinical trials are discussed herein.
منابع مشابه
Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD). AD is characterized by toxic β-amyloid (Aβ) peptides produced by β- and γ-secretase-mediated cleavage of the amyloid precursor protein (APP). β-secretase inhibitors reduce Aβ levels, but mechanism-based side effects arise because they also inhibit β-cleavage of non-amyloid substrates like Neure...
متن کاملThe cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
The cysteine protease cathepsin B is a potential drug target for reducing brain amyloid-β (Aβ) and improving memory in Alzheimer's disease (AD), as reduction of cathepsin B in transgenic mice expressing human wild-type amyloid-β protein precursor (AβPP) results in significantly decreased brain Aβ. Cathepsin B cleaves the wild-type β-secretase site sequence in AβPP to produce Aβ, and cathepsin B...
متن کاملChronic Treatment with the -Secretase Inhibitor LY-411,575 Inhibits -Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation*
Inhibition of -secretase, one of the enzymes responsible for the cleavage of the amyloid precursor protein (APP) to produce the pathogenic -amyloid (A ) peptides, is an attractive approach to the treatment of Alzheimer disease. In addition to APP, however, several other -secretase substrates have been identified (e.g. Notch), and altered processing of these substrates by -secretase inhibitors c...
متن کاملInhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
Deposition of amyloid β protein (Aβ) to form neuritic plaques in the brain is the pathological hallmark of Alzheimer's disease (AD). Aβ is generated from sequential cleavages of the β-amyloid precursor protein (APP) by the β- and γ-secretases, and β-site APP-cleaving enzyme 1 (BACE1) is the β-secretase essential for Aβ generation. Previous studies have indicated that glycogen synthase kinase 3 ...
متن کاملNpgrj_nn_1531 1343..1349
In Alzheimer disease, increased b-secretase (BACE1) activity has been associated with neurodegeneration and accumulation of amyloid precursor protein (APP) products. Thus, inactivation of BACE1 could be important in the treatment of Alzheimer disease. In this study, we found that lowering BACE1 levels using lentiviral vectors expressing siRNAs targeting BACE1 reduced amyloid production and the ...
متن کامل